DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
IPO Year: 2014
Exchange: NASDAQ
Website: dbv-technologies.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/4/2023 | Hold → Buy | Societe Generale | |
| 12/16/2022 | Neutral → Sell | Goldman | |
| 5/10/2022 | $6.00 → $1.50 | Buy → Neutral | Goldman |
| 12/21/2021 | $8.00 → $5.00 | Market Outperform | JMP Securities |
| 12/21/2021 | $14.00 → $10.00 | Buy | HC Wainwright & Co. |
| 9/14/2021 | Hold → Buy | Societe Generale |
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
3 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
F-6 POS - DBV Technologies S.A. (0001613780) (Subject)
8-K - DBV Technologies S.A. (0001613780) (Filer)
10-Q - DBV Technologies S.A. (0001613780) (Filer)
8-K - DBV Technologies S.A. (0001613780) (Filer)
8-K - DBV Technologies S.A. (0001613780) (Filer)
8-K - DBV Technologies S.A. (0001613780) (Filer)
10-Q - DBV Technologies S.A. (0001613780) (Filer)
S-8 - DBV Technologies S.A. (0001613780) (Filer)
8-K - DBV Technologies S.A. (0001613780) (Filer)
8-K - DBV Technologies S.A. (0001613780) (Filer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
Societe Generale upgraded DBV Technologies from Hold to Buy
Goldman downgraded DBV Technologies from Neutral to Sell
Goldman downgraded DBV Technologies from Buy to Neutral and set a new price target of $1.50 from $6.00 previously
JMP Securities reiterated coverage of DBV Technologies with a rating of Market Outperform and set a new price target of $5.00 from $8.00 previously
HC Wainwright & Co. reiterated coverage of DBV Technologies with a rating of Buy and set a new price target of $10.00 from $14.00 previously
Societe Generale upgraded DBV Technologies from Hold to Buy
Societe Generale downgraded DBV Technologies from Hold to Sell
Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to five (5) ordinary shares (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on or
Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2024. The quarterly and nine months financial statements were approved by the Board of Directors on November 6, 2024. Financial Highlights for the third quarter Ended September 30, 2024 The Company's interim condensed consolidated financial statements for the nine months ended September 30, 2024, are prepared in accordance with accounting principles generally ac
Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025 European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7
Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, October 24 – 28th, 2024 in Boston, Massachusetts. This year's meeting will feature a "Product Theater" on What Defines an Optimal Peanut Allergy Treatment? During this panel discussion, Drs. Shahzad Mustafa, Edwin Kim, Julia Upton, and CEO of Food Allergy Research and Education (FAACT), Eleanor Garrow-Holding will engage in a discussion around hallmarks of an optimal treatment
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 09/30/2024 96,501,526 Total gross of voting rights: 96,501,526 Total net* of voting rights: 96,199,467 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version
Châtillon, France, September 4, 2024 DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference DBV Technologies (XLON:0QAJ), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 3:00 pm ET, in New York City. A live webcast of the presentation can be accessed here, and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/events/ A replay will also be available on DBV Technologies' website for 90 d
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights07/31/2024 96,498,927 Total gross of voting rights: 96,498,927 Total net* of voting rights: 96,214,457 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the "Company"), today announced the filing, for the semester ended June 30, 2024, of its Half-Year Report with the French market authority, "Autorité des Marchés Financiers" ("AMF"). The 2024 Half-Year Report can be consulted or downloaded from the Company's website (www.dbv-technologies.com) in the section
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024 DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA's protocol queries regarding patch wear-time in COMFORT ToddlersDBV closes Q2 2024 with a cash balance of $66.2 million; due to cost-saving measures, the Company's cash runway is extended into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update. Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call: United States: +1-877-346-6112International: +1-848-280-6350 A live webcast of the call will be a
Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent
Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. "I am pleased to welcome Virginie to the DBV Executive Committee to lead our global financial organization," said Daniel Tassé, Chief Executive Officer, DBV Tech
Montrouge, France, October 3, 2022 DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that Mr. Timothy E. Morris, Independent Director and Member of the Audit Committee of the Board of Directors ("the Board"), was appointed as Chairperson of the Board's Audit Committee in replacement of Ms. Viviane Monges, who resigned from the Board effective October 3, 2022. DBV also announced the Board's provisional appointment of Ms. Daniele Guyot-Caparros as Independent Director to fill Ms. Monges' vacancy, effective October
Appoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of DirectorsNames Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnology and large pharmaceutical companies, as Chief Medical Officer Reports inducement grant to Dr. Truitt under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of Timothy E. Mo
GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the appointment of Douglas Larson as Chief Financial Officer, succeeding Douglas Beck effective September 1, 2021. Mr. Beck will remain a consultant to the Company and is expected to work closely with Mr. Larson and the Beyond Air leadership team to ensure a seamless transition of CFO responsibilities. Dougl
Montrouge, France, May 19, 2021 DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its Board of Directors DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. DBV Technologies' General Meeting was chaired by Michel de Rosen, Chairman of DBV Technologies' Board of Directors, in a closed virtual session without the physical presence of shareholders or any other person authorized to attend, at DBV Technologies' registered office. The Company's shareholders approved all
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G - DBV Technologies S.A. (0001613780) (Subject)
SC 13G - DBV Technologies S.A. (0001613780) (Subject)
SC 13D/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13D/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025 European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024 DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA's protocol queries regarding patch wear-time in COMFORT ToddlersDBV closes Q2 2024 with a cash balance of $66.2 million; due to cost-saving measures, the Company's cash runway is extended into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update. Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call: United States: +1-877-346-6112International: +1-848-280-6350 A live webcast of the call will be a
Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Strengthened executive leadership team in preparation for BLA submissionReported cash and cash equivalents of $141 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023. The audit procedure
Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m. ET to review full year 2023 financial results and provide a business update. Interested participants may access this call via the below teleconferencing numbers and reference the DBV Technologies call: United States: 1-844-481-2866International: 1-412-317-1859 A live webcast of th
Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. Notably, 81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.55.9% of subjects completed the oral food challenge at a cumulative dose of 3,444 mg without meeting stopping criteria.Among treatment-arm subjects from EPITOPE, there were no treatment-related anaphylactic or serious treatment-related adverse events in the second year of active
Montrouge, France, October 31, 2023 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results DBV has received written feedback from the U.S. Food and Drug Administration (FDA) clarifying design elements for both the COMFORT Toddlers and COMFORT Children supplemental safety studies.Both supplemental safety studies will have harmonized, simplified protocol language on how the product should be used. The COMFORT Toddlers study will apply the same eligibility criteria as EPITOPE, DBV's successful Phase 3 efficacy study in toddlers 1-3 years.DBV will submit the final protocol for COMFORT Toddl
Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, October 31st, at 5:00 p.m. ET to review third quarter 2023 financial results and provide a business update. Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call: United States: 1-844-481-2866International: 1-412-317-1859 A live webcast of the call will be available on the In
Montrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results Received feedback from U.S. Food and Drug Administration (FDA) on DBV's two supplemental safety studies in toddlers (ages 1 – 3 years) and children (ages 4 – 7 years).The two Phase 3 pivotal safety studies will be named COMFORT Toddlers (1 – 3 years) and COMFORT Children (4 – 7 years).COMFORT Toddlers will be a 6-month safety study, consistent with agreement previously reached with FDA on the COMFORT Children safety study.The Company expects to seek final alignment with FDA on the COMFORT protocols
Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, July 31st, at 5:00 p.m. ET to report first half 2023 financial results and provide a corporate update. Participants may access this event via the below teleconferencing numbers and asking to join the DBV Technologies call: United States: 1-844-481-2866 International: +1-412-317-1859 A live webcast of the call will be availab
Gainers Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 124.3% to $0.98 during Thursday's pre-market session. The company's market cap stands at $4.9 million. Virax Biolabs Group (NASDAQ:VRAX) stock increased by 116.82% to $2.32. The company's market cap stands at $5.4 million. iSpecimen (NASDAQ:ISPC) shares increased by 36.65% to $0.44. The market value of their outstanding shares is at $4.3 million. 60 Degrees (NASDAQ:SXTP) shares moved upwards by 28.26% to $0.37. The company's market cap stands at $4.4 million. CERo Therapeutics Hldgs (NASDAQ:CERO) shares rose 27.08% to $1.15. The market value of their outstanding shares is at $17.3 million. OneMedNet (NASDAQ:ONMD) stock incre
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the "ADS Ratio Change") to be effective on or about June 3rd, 2024. The Company now anticipates that the ADS Ratio Ch
DBV Technologies Announces Plan to Implement ADS Ratio ChangeDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the "ADS Ratio Change"). The Company anticipates that the ADS
Gainers Lucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 123.5% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million. SINTX Techs (NASDAQ:SINT) stock moved upwards by 19.67% to $0.15. The market value of their outstanding shares is at $18.7 million. As per the press release, Q1 earnings came out 3 days ago. Dynatronics (NASDAQ:DYNT) stock increased by 16.7% to $0.51. The market value of their outstanding shares is at $2.7 million. Ontrak (NASDAQ:OTRK) shares moved upwards by 15.99% to $0.31. The company's market cap stands at $14.8 million. The company's, Q1 earnings came out 2 days ago. NovaBay Pharmaceuticals (AME
HC Wainwright & Co. analyst Andrew Fein maintains DBV Technologies (NASDAQ:DBVT) with a Buy and lowers the price target from $10 to $5.
DBV Technologies (NASDAQ:DBVT) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $(0.21) by 233.33 percent. This is a 227.27 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $1.40 million which missed the analyst consensus estimate of $2.27 million by 38.33 percent. This is a 36.36 percent decrease over sales of $2.20 million the same period last year.
Gainers Allarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. Emergent BioSolutions (NYSE:EBS) shares moved upwards by 52.84% to $2.95. The market value of their outstanding shares is at $154.5 million. As per the press release, Q1 earnings came out yesterday. Aptevo Therapeutics (NASDAQ:APVO) stock rose 35.41% to $1.3. The company's market cap stands at $4.6 million. Context Therapeutics (NASDAQ:CNTX) stock rose 34.55% to $1.83. The company's market cap stands at $29.2 million. Skye Bioscience (NASDAQ:SKYE) stock increased by 25.09% to $16.0. The company's market
Gainers Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 33.1% to $0.49 during Monday's pre-market session. The market value of their outstanding shares is at $8.3 million. XTL Biopharmaceuticals (NASDAQ:XTLB) shares increased by 19.31% to $1.05. The market value of their outstanding shares is at $5.7 million. 2seventy bio (NASDAQ:TSVT) shares rose 17.7% to $4.72. The company's market cap stands at $242.1 million. DBV Technologies (NASDAQ:DBVT) shares moved upwards by 13.92% to $0.9. The company's market cap stands at $173.1 million. Elicio Therapeutics (NASDAQ:ELTX) shares increased by 13.2% to $5.66. The market value of their outstanding shares is at $54.3 million. Moleculin
DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.060) per share. The company reported quarterly sales of $8.875 million which beat the analyst consensus estimate of $412.000 thousand by 2.05K percent. This is a 758.38 percent increase over sales of $(1.348 million) the same period last year.
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. • Stevanato Gr (NYSE:STVN) is likely to report quarterly earnings at $0.21 per share on revenue of $354.31 million. • ABM Indus (NYSE:ABM) is projected to report quarterly earnings at $0.71 per share on revenue of $2.01 billion. • Bilibili (NASDAQ:BILI) is likely to report quarterly loss at $0.22 per share on revenue of $887.26 million. • BJ's Wholesale Club (NYSE:BJ) is projected to report quarterly earnings at $1.06 per share on revenue of $5.39 billion. • Burlington Stores (NYSE:BURL) is estimated to report quarterly earnings at $3.30 per